Ogun AYDOĞAN, Osman BOZBIYIK, Deniz UÇAR, Murat ÖZDEMİR, Şafak ÖZTÜRK, Mutlu ÜNVER, Levent YENİAY, Murat KAPKAÇ, Rasih YILMAZ, Erdem CARTİ

MEME KANSERİNDE HORMON RESEPTÖRÜ SAĞKALIM VE METASTAZ ÜZERİNDE BELİRLEYİCİDİR

Triple Negatif TN meme kanseri sınırlı tedavi alternatiflerine sahiptir. Bu grupta tedavinin fayda şansı azdır. Prognoz kötüdür ve diğer tiplere nazaran daha saldırgan seyirlidir. Daha fazla aksiller lenf nodu tutulumu, erken dönemde ve özellikle iç organlara erken metastaz karakteristiktir. Az sayıda tedavi alternatifine sahip TN meme kanseri aralarındaki farklılıkların da ortaya konulabilmesi için yeni tedavi protokollerinden fayda gören Luminal B LB meme kanseri ile kıyaslanmıştır. Bu iki grup arasındaki farklılıkların ortaya konması ümit vadeden tedavilerin oluşturulabilmesi ve takip stratejilerinin geliştirilebilmesine yardımcı olabilir. Bu çalışmaya Ege üniversitesi Genel Cerrahi Servisinde 1998 ile 2007 yılları arasında bilinen metastazı olmayan 91 TN östrojen reseptör negatif, progesteron reseptör negatif ve insan epidermal büyüme faktör reseptörü 2 negatif ve 183 Luminal B östrojen reseptör pozitif, progesteron reseptör pozitif ve insan epidermal büyüme faktör reseptörü 2 pozitif hasta dâhil edilmiştir TN grubunda metastazsız sağkalım oranları 12 ve 24. aylarda LB gruba nazaran daha düşük olmasına rağmen istatistiksel olarak anlamlı değildi. Bununla birlikte 36 Log Rank p=0.021 ve 60. Log Rank p=0.041 aylarda anlamlı bir fark bulundu. TN fenotipi erken zamanda artmış iç organ metastaz riski nedeni ile prognozda negatif etki göstermektedir. Bu bulgu takip ve tedaviye yaklaşımda stratejik bir değere sahiptir

Anahtar Kelimeler:

Meme kanseri, Üçlü negatif meme kanseri, Luminal tip meme kanseri

HORMONE RECEPTOR STATUS DEFINES SURVIVAL AND METASTASIS RATE IN BREAST CANCER

Triple Negative TN breast cancer has few treatment alternatives. The chance for cure is poor, prognosis is bad and it is more aggressive than other types of breast cancers. Axillary involvement and early solid organ metastasis especially internal organs are more frequent. TN breast cancer with less treatment alternative was compared to divulge the differences with Luminal B LB which showed better outcomes with new treatment protocols. Comparison of these two groups may help us to produce promising treatment and follow up protocols. In Ege University General Surgery Department 91 TN estrogen negative, progesterone negative and human epidermal growth factor negative and 183 LB estrogen positive, progesterone positive and human epidermal growth factor positive patients operated between 1998 and 2007 were included in this study Survival without metastasis were lower than in TN group than LB group at 12th and 24th months but these were statistically indifferent. At 36th and 60th months however differences were significant Log Rank p=0.021 and p=0.041 respectively TN phenotype has negative prognosis due to the effect of early high internal organ metastasis rate. This finding has a strategic importance in treatment and follow up approach

Keywords:

Breast cancer, Triple negative breast cancer, Luminal type breast cancer,

PDF

___

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen progesterone receptor (PR)-negative, and HER-2-negative invasive breast cancer, the so-called population-based study from the California cancer Registry. Cancer 2007; 109:1721-8. A 2.
Dawson SJ, Provenzano E, Caldas C. Triple-negative breast cancers: clinical and prognostic implications. Eur J Cancer 2009; 45 (suppl 1):27-40. 3.
Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8:235-44. 4.
Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R.p53 and vascular- endothelial-growth factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 2000; 89: 51-62. 5.
Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 2001; 61: 2256-60. 6.
Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. BreastCancerRes 2009; 11:R31. 7.
Luck AA, Evans AJ, Green AR, Rakha EA, Paish C, Ellis IO. The influence of basal phenotype on the metastatic pattern of breast cancer. ClinOncol (R CollRadiol) 2008; 20:40-5. 8.
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple- negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13(15 Pt 1):4429-34. 9.
Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, et al. Race and triple negative threats to breast cancer survival: a population based study in Atlanta, GA.Breast Cancer Res Treat 2009; 113:357- 70. 10.
Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M. Triple negative breast cancer: current status and prospective targeted treatment based on HER1 (EGFR), TOP2A, and C-MYC gene assessment. Biomed Pap Repub2009; 153:13-7. 11.
Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109:25-32. 12.
Dees EC, Shulman LN, Souba WW, Smith BL. Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? An algorithm for assessment of impact of axillary dissection. Ann Surg1997; 226:279- 86 13.
Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Loco-regional relapse conservatively managed triple negative early stagebreast 24:5652-7. in cancer. J ClinOncol2006; 14.
Carey LA, Perou CM, LivasyCA, Dressler LG, Cowan D, Conway K, et al. Race, breastcancer subtypes, and survival in the Carolina Breast CancerStudy. JAMA 2006; 295:2492-502. 15.
Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH, Siram SM, Leffall LD Jr, et al. Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American women. Am J Surg 2008; 195:153- 8. 16.
Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, et al. Triple- Negative or HER-2- Positive Status Predicts Higher Rates of Locoregional Recurrence in Node-Positive Breast Cancer Patients After Mastectomy. Int J RadiatOncolBiol Phys.2011; 80:1095-101 17.
Sachdev JC, Ahmed S, Mirza MM, Farooq A, Kronish L, Jahanzeb M. Does race affect outcomes in triple negative breast cancer? Breast Cancer (Auckl). 2010; 4:23- 33. 18.
Kuroda H, Nakai M, Ohnisi K, Ishida T, Kuroda M, Itoyama S. Vascular invasion in triple-negative carcinoma of the breast identified by endothelial lymphatic and blood vessel 2010;18:324-9. J SurgPathol 19.
Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009; 115:423-8. 20.
Lin C, Chien SY, Chen LS, Kuo SJ, Chang TW, Chen DR. Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer 2009; 9:192. 21.
Rakha E, Reis-Filho JS. Basal-like breast carcinoma, from expression profiling to routine practice. Arch Pathol Lab Med 2009; 133:860-7. 22.
Weigelt B, Peterse JL, van´ t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5: 591-602. 23.
Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 2007;9:R4 24.
Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008;113:2638-45 25.
Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin 5/6, and overexpress HER-2 or EGFR. Am J SurgPathol2006; 30:1097- 1104. 26.
Rodríguez-Pinilla SM, Sarrió D, Honrado E, Hardisson D, Calero F, Benitez J, et al. Prognostic
phenotype and fascin expression in node- negative invasive breast cancers. Clin Cancer Res 2006;12:1533-1539. of basal-like 27.
Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtiö J, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 2009; 20:1639-46. 28.
Solin LJ, Hwang WT, Vapiwala N. Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma.Clin Breast Cancer 2009; 9:96-100.
Yazının alınma tarihi:24.01.2014
Kabül tarihi:15.02.2014
Online basım:15.02.2014